Moderna's Options Market Reflects Mixed Sentiment Amid Price Decline

Moderna (MRNA) shows mixed options sentiment with a put-to-call ratio of 0.63, despite a recent price decrease of $1.35. Implied volatility has decreased by 6.03%, but remains high, and the put-call skew suggests increased interest in downside protection. The company's financial performance reflects revenue growth of -41.3%, significant losses, and a strong liquidity position. Valuation metrics show a P/S ratio of 6.88 and a P/B ratio of 1.64, with an analyst target price of $38.51. Investors should consider risks associated with financial health grades, sector-specific risks, and volatility.